Medindia

X

CryoCath to present at Canaccord Adams Cardiovascular Conference

Saturday, November 10, 2007 General News J E 4
Advertisement
MONTREAL, Nov. 9 /PRNewswire-FirstCall/ - CryoCath Technologies Inc. (TSX:CYT), the global leader in cryotherapy products to treat cardiac arrhythmias,today announced that Jan Keltjens, President and CEO of CryoCath, will presentat the Canaccord Adams Cardiovascular Conference at the Waldorf Astoria in NewYork City on Tuesday, November 13 at 11:45 am ET. Mr. Keltjens will present onthe Company's market outlook and discuss some recent events and upcomingmilestones, including the STOP AF IDE Trial for Arctic Front(R), the Company'sminimally invasive cryo-balloon catheter designed specifically to treatparoxysmal atrial fibrillation.

A live webcast of CryoCath's presentation will be available atwww.cryocath.com.

About CryoCath

CryoCath - www.cryocath.com - is a medical technology company that leadsthe world in cryotherapy products to treat cardiovascular disease. With apriority focus on providing physicians with a complete solution of catheterproducts to treat cardiac arrhythmias, CryoCath has multiple products approvedin the U.S., across Europe and several ROW countries. The Company isdeveloping additional products to expand its pipeline of products to treatcardiac arrhythmias.

This press release includes "forward-looking statements" that are subjectto risks and uncertainties, including with respect to the timing of regulatorytrials and their outcome. For information identifying legislative orregulatory, economic, climatic, currency, technological, competitive and otherimportant factors that could cause actual results to differ materially fromthose anticipated in the forward looking statements, see CryoCath's annualreport available at www.sedar.com under the heading Risks and Uncertainties inthe Management's Discussion and Analysis section.

SOURCE CryoCath Technologies Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
NTMir Announces Research Grants for Epidemiology a...
S
PROFNET EXPERT & DAILY TOPIC ALERTS: Health and Li...